文献速递治疗药物监测与药物基因组学特殊人群用药

SLCO1B1*5 功能降低基因型对男女他汀疗效的长期影响

Statin treatment effectiveness and the SLCO1B1*5 reduced function genotype: Long-term outcomes in women and men.
PubMed 文献 · Br J Clin Pharmacol · 2022-02-14

女性纯合子 SLCO1B1*5 者基线高胆固醇比例更高(48.4% vs 41.7%,OR 1.31),且停药风险增加(29.5% vs 25.7%,HR 1.19),男性中基因效应减弱。

要点

  • 女性 SLCO1B1*5 纯合子胆固醇控制更差,高胆固醇风险 OR 1.31。
  • 女性 SLCO1B1*5 纯合子他汀停药风险增加,HR 1.19。
  • 男性中 SLCO1B1*5 对胆固醇控制影响减弱,仅第一年与停药相关。

核心结论

  • 在社区人群中,SLCO1B1*5 功能降低变异对女性胆固醇控制和治疗时长的影响远大于男性。
  • 改善女性他汀疗效可能需要考虑 SLCO1B1*5 基因型指导的他汀选择。

研究设计与样本

  • 治疗时长 1 个月至 29 年,平均 5.7 年。

主要发现

  • 男性高胆固醇比例较少,且基因型效应减弱。
  • SLCO1B1*5 组每 100 他汀治疗年停药 5 例,正常功能组 4 例。

临床怎么用

  • 对女性使用辛伐他汀或阿托伐他汀时,可考虑 SLCO1B1*5 基因型以评估胆固醇控制不佳和停药风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To estimate the effect of rs4149056 (SLCO1B1*5) genotype (decreases statin transport) on cholesterol control and treatment duration in male and female primary care patients prescribed common statin medications. METHODS AND ANALYSIS: This study comprised 69 185 European-ancestry UK Biobank cohort participants prescribed simvastatin or atorvastatin (aged 40-79 years at first prescription, treatment duration 1 month to 29 years, mean 5.7 years). Principal outcomes were clinically high total cholesterol (>5 mmol/L) at baseline, plus treatment discontinuation. RESULTS: A total of 48.4% of 591 females homozygous for SLCO1B1*5 decreased function genotype had raised cholesterol vs 41.7% of those with functioning SLCO1B1 (odds ratio 1.31, 95% confidence interval [CI] 1.1-1.55, P = .001). Fewer males had high cholesterol and the genotype effect was attenuated. In primary care prescribing, females homozygous for SLCO1B1*5 were more likely to stop receiving these statins (29.5%) than women with normal SLCO1B1 (25.7%) (hazard ratio [HR] 1.19, 95% CI 1.03-1.37, P = .01), amounting to five discontinuations per 100 statin-years in the SLCO1B1*5 group vs four in the normal SLCO1B1 function group. This remained significant after the first year of treatment (HR for discontinuing >1 year after first prescription 1.3, 95% CI 1.08-1.56, P = .006). In men SLCO1B1*5 was only associated with treatment discontinuation in the first year. CONCLUSIONS: In this large community sample of patients on commonly prescribed statins, the SLCO1B1*5 decreased function variant had much larger effects on cholesterol control and treatment duration in women than in men. Efforts to improve the effectiveness of statin therapy in women may need to include SLCO1B1*5 genotype-guided statin selection.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Türkmen D, Masoli JAH, Kuo CL, et al. Statin treatment effectiveness and the SLCO1B1*5 reduced function genotype: Long-term outcomes in women and men. Br J Clin Pharmacol. 2022. PMID: 35083771. doi:10.1111/bcp.15245

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。